அமோய் பரிசோதனை இணை லிமிடெட் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from அமோய் பரிசோதனை இணை லிமிடெட். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In அமோய் பரிசோதனை இணை லிமிடெட் Today - Breaking & Trending Today

AmoyDx® Pan Lung Cancer PCR Panel Receives MHLW Approval as


AmoyDx® Pan Lung Cancer PCR Panel Receives MHLW Approval as Companion Diagnostic for 9 Targeted Therapies for Use in Patients with Advanced Non-Small Cell Lung Cancer
PREMIA Holdings (HK) Ltd.
Hong Kong, HONG KONG
TOKYO and XIAMEN, China, June 30, 2021 (GLOBE NEWSWIRE) Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the AmoyDx
® Pan Lung Cancer PCR Panel (the “AmoyDx PLC Panel”), an in vitro diagnostic reagent developed as a companion diagnostic for multiple anti-cancer agents, was approved by Ministry of Health, Labour and Welfare (MHLW) for production and marketing in Japan on June 25, 2021. ....

South Korea , Pan Lung , Paul Huang , Kenji Iwakabe , Wenn Sun , Panel The Amoydx , Precision Medicine Asia Co Ltd , Riken Genesis Co Ltd , Ministry Of Health , Amoy Diagnostics Co Ltd , Marketing Department , Pan Lung Cancer , Riken Genesis , Li Mou Zheng , Marketing Authorization , Precision Medicine Asia , தெற்கு கொரியா , பால் ஹுவாங் , றிக்கேன் ஜநெஸிஸ் இணை லிமிடெட் , அமைச்சகம் ஆஃப் ஆரோக்கியம் , அமோய் பரிசோதனை இணை லிமிடெட் , சந்தைப்படுத்தல் துறை , றிக்கேன் ஜநெஸிஸ் , சந்தைப்படுத்தல் அங்கீகாரம் , ப்ரிஸிஶந் மருந்து ஆசியா ,

Global Liquid Biopsy Market Review 2019-2020 and Forecast 2021-2025 with Profiles of Over 200 Competitors


Share this article
Share this article
ResearchAndMarkets.com s offering.
The scope of the report includes liquid biopsy technologies, applications, industry subsegments, biomarker technologies, major funding initiatives, patents and companies. The market sizes for liquid biopsy diagnostics are given for 2019, 2020 and 2025 (forecasted).
Liquid biopsy is creating a paradigm shift in medicine, and this is opening significant market opportunities. These market segments are particularly promising for the following liquid biopsy applications: noninvasive prenatal screening for average-risk populations; cancer screening and early detection; and recurrence monitoring for cancer patients.
Biomarker types of most interest include cell-free DNA (cfDNA), circulating tumor cells (CTCs) and exosomes. Ongoing advances in sensitive molecular technologies such as next-generation DNA sequencing (NGS) and digital polymerase chain reaction (dPCR) enable the detection of biomarker ....

United States , Diamir Bio , Cegat Gmbh , Pacific Biosciences , Cambridge Epigenetix , Twinstrand Biosciences , Telexos Gmbh , Codiak Biosciences , Capio Biosciences , Circulogene Theranostics , Laura Wood , Koninklijke Philips , Sysmex Inostics Gmbh , Apostle Inc , Burning Rock Biotech Ltd , Quantapore Inc , Biofluidica Inc , Namocell Inc , Nrichdx Inc , Dnanexus Inc , Seracare Life Sciences Inc , Id Solutions , Yikon Genomics Co Ltd , Labrinth Biotech Inc , Exosome Sciences Inc , Quantgene Inc ,